MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Rejects Apple Trade Secret Theft Claims 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Xiaomi Shares Jump on Europe EV Expansion Plan 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
NEW YORK, March 05, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that members of the company’s management team will present at two upcoming investor conferences:
- Cowen & Company 38th Annual Health Care Conference
Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid, will present a corporate overview on Monday, March 12, 2018 at 2:10 p.m. ET. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, MA.
- BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
Yaron Werber, M.D., chief business and financial officer of Ovid, will present a corporate overview on Friday, March 23, 2018 at 10:00 a.m. ET. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York, NY.
Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. Archived replays of the webcasts will be available on the company's website for two weeks following each live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
[email protected]
